Increased risk of infection with SARS-CoV-2 Omicron BA.1 compared with Delta in vaccinated and previously infected individuals, the Netherlands, 22 November 2021 to 19 January 2022-Reference-Cited by-同舟云学术

Increased risk of infection with SARS-CoV-2 Omicron BA.1 compared with Delta in vaccinated and previously infected individuals, the Netherlands, 22 November 2021 to 19 January 2022

Published:2022-01-27 Issue:4 Volume:27 Page:
ISSN:1560-7917
Container-title:Eurosurveillance
language:en
Short-container-title:

Author:

Eggink Dirk¹^ORCID,Andeweg Stijn P¹^ORCID,Vennema Harry¹,van Maarseveen Noortje²³,Vermaas Klaas³,Vlaemynck Boris⁴,Schepers Raf⁴,van Gageldonk-Lafeber Arianne B¹,van den Hof Susan¹,Reusken Chantal BEM¹,Knol Mirjam J¹

Affiliation:

1. Center for Infectious Disease Control, WHO COVID-19 reference laboratory, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands

2. Department of Medical Microbiology, University Medical Center Utrecht, Utrecht, the Netherlands

3. Saltro Diagnostic Center for Primary Care, Utrecht, The Netherlands

4. SYNLAB, Heppignies, Belgium

Abstract

Infections with the Omicron SARS-CoV-2 variant are rapidly increasing worldwide. Among 174,349 SARS-CoV-2-infected individuals (≥ 12 years), we observed an increased risk of S gene target failure, predictive of the Omicron variant, in vaccinated (odds ratio (OR): 3.6; 95% confidence interval (CI): 3.4–3.7) and previously infected individuals (OR: 4.2; 95% CI: 3.8–4.7) compared with infected naïve individuals. This suggests vaccine- or infection-induced immunity against SARS-CoV-2 infections is less effective against the Omicron than the Delta variant.

Publisher

European Centre for Disease Control and Prevention (ECDC)

Subject

Virology,Public Health, Environmental and Occupational Health,Epidemiology

Reference26 articles.

1. World Health Organization (WHO). Tracking SARS-CoV-2 variants. Geneva: WHO. [Accessed: 30 Dec 2021]. Available from: https://www.who.int/en/activities/tracking-SARS-CoV-2-variants

2. European Centre for Disease Prevention and Control (ECDC). Epidemiological update: Omicron variant of concern (VOC) – data as of 16 December 2021 (12:00). Stockholm: ECDC; 2021. Available from: https://www.ecdc.europa.eu/en/news-events/epidemiological-update-omicron-data-16-december

3. Barnard RC, Davies N, Pearson CAB, Jit M, Edmunds J. Modelling the potential consequences of the Omicron SARS-CoV-2 variant in England | Centre for Mathematical Modelling of Infectious Diseases Repository. London: London School of Hygiene & Tropical Medicine; 2021. Preprint. Available from: https://cmmid.github.io/topics/covid19/omicron-england.html

4. European Centre for Disease Prevention and Control (ECDC). Weekly epidemiological update: Omicron variant of concern (VOC) – week 2 (data as of 20 January 2022) EU/EEA. Stockholm: ECDC; 2022. Available from: https://www.ecdc.europa.eu/en/news-events/weekly-epidemiological-update-omicron-variant-concern-voc-week-2-data-20-january-2022

5. Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization.;Cele;Nature,2021

Cited by 63 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hospitalisations and Deaths Averted by COVID-19 Vaccination in Navarre, Spain, 2021–2022;Vaccines;2024-01-07

2. Epidemic Financing Facilities: Pandemic Bonds and Endemic Swaps;North American Actuarial Journal;2023-12-18

3. Risk factors and outcomes for repeat COVID-19 infection among patients with systemic autoimmune rheumatic diseases: A case-control study;Seminars in Arthritis and Rheumatism;2023-12

4. Assessment of hybrid population immunity to SARS-CoV-2 following breakthrough infections of distinct SARS-CoV-2 variants by the detection of antibodies to nucleoprotein;Scientific Reports;2023-10-26

5. Real-Time Analysis of SARS-CoV-2-Induced Cytolysis Reveals Distinct Variant-Specific Replication Profiles;Viruses;2023-09-16